The DOI matches its Crossref record; 117 of the 117 references it cites were found in a registry or an index.
Old Drugs as New Treatments for Neurodegenerative Diseases
Open accessAbstract
Neurodegenerative diseases are increasing in number, given that the general global population is becoming older. They manifest themselves through mechanisms that are not fully understood, in many cases, and impair memory, cognition and movement. Currently, no neurodegenerative disease is curable, and the treatments available only manage the symptoms or halt the progression of the disease. Therefore, there is an urgent need for new treatments for this kind of disease, since the World Health Organization has predicted that neurodegenerative diseases affecting motor function will become the second-most prevalent cause of death in the next 20 years. New therapies can come from three main sources: synthesis, natural products, and existing drugs. This last source is known as drug repurposing, which is the most advantageous, since the drug’s pharmacokinetic and pharmacodynamic profiles are already established, and the investment put into this strategy is not as significant as for the classic development of new drugs. There have been several studies on the potential of old drugs for the most relevant neurodegenerative diseases, including Alzheimer’s disease, Parkinson’s disease, Huntington’s disease, Multiple Sclerosis and Amyotrophic Lateral Sclerosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Poewe, W., Seppi, K., Tanner, C. M., Halliday, G. M., Brundin, P., Volkmann, J., Schrag, A.-E., & Lang, A. E. (2017) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2017.13 · Cited by 5,415
Drug repositioning: identifying and developing new uses for existing drugs
Ashburn, T. T., & Thor, K. B. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1468 · Cited by 3,237
Scheltens, P., Blennow, K., Breteler, M. M. B., de Strooper, B., Frisoni, G. B., Salloway, S., & Van der Flier, W. M. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01124-1 · Cited by 3,125
Rowland, L. P., & Shneider, N. A. (2001) · New England Journal of Medicine · doi:10.1056/nejm200105313442207 · Cited by 1,812
Multiple Sclerosis: An Immune or Neurodegenerative Disorder?
Trapp, B. D., & Nave, K.-A. (2008) · Annual Review of Neuroscience · doi:10.1146/annurev.neuro.30.051606.094313 · Cited by 1,724
Bates, G. P., Dorsey, R., Gusella, J. F., Hayden, M. R., Kay, C., Leavitt, B. R., Nance, M., Ross, C. A., Scahill, R. I., Wetzel, R., et al. (2015) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2015.5 · Cited by 1,641
A review on Alzheimer's disease pathophysiology and its management: an update
Kumar, A., Singh, A., & Ekavali (2015) · Pharmacological Reports · doi:10.1016/j.pharep.2014.09.004 · Cited by 1,578
Huntington's disease: a clinical review
Roos, R. A. (2010) · Orphanet Journal of Rare Diseases · doi:10.1186/1750-1172-5-40 · Cited by 1,037
Fox, S. H., Katzenschlager, R., Lim, S., Barton, B., de Bie, R. M. A., Seppi, K., Coelho, M., Sampaio, C., & on behalf of the Movement Disorder Society Evidence‐Based Medicine Committee (2018) · Movement Disorders · doi:10.1002/mds.27372 · Cited by 1,002
Hartung, H.-P., Gonsette, R., Konig, N., Kwiecinski, H., Guseo, A., Morrissey, S. P., Krapf, H., & Zwingers, T. (2002) · The Lancet · doi:10.1016/s0140-6736(02)12023-x · Cited by 946
A systemic view of Alzheimer disease — insights from amyloid-β metabolism beyond the brain
Wang, J., Gu, B. J., Masters, C. L., & Wang, Y.-J. (2017) · Nature Reviews Neurology · doi:10.1038/nrneurol.2017.111 · Cited by 808
Neurodegenerative disease: models, mechanisms, and a new hope
Gitler, A. D., Dhillon, P., & Shorter, J. (2017) · Disease Models & Mechanisms · doi:10.1242/dmm.030205 · Cited by 739
McClean, P. L., Parthsarathy, V., Faivre, E., & Hölscher, C. (2011) · The Journal of Neuroscience · doi:10.1523/jneurosci.0529-11.2011 · Cited by 698
Exenatide and the treatment of patients with Parkinson's disease
Aviles-Olmos, I., Dickson, J., Kefalopoulou, Z., Djamshidian, A., Ell, P., Soderlund, T., Whitton, P., Wyse, R., Isaacs, T., Lees, A., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci68295 · Cited by 529
Insulin and the insulin receptor in experimental models of learning and memory
Zhao, W.-Q., Chen, H., Quon, M. J., & Alkon, D. L. (2004) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2004.02.045 · Cited by 502
(1973) · BMJ · doi:10.1136/bmj.2.5863.432 · Cited by 488
Li, N.-C., Lee, A., Whitmer, R. A., Kivipelto, M., Lawler, E., Kazis, L. E., & Wolozin, B. (2010) · BMJ · doi:10.1136/bmj.b5465 · Cited by 486
Farace, C., Melguizo, C., Asara, Y., Álvarez, P., Prados, J. C., Tolu, P., Delogu, G., Aránega, A., & Madeddu, R. (2011) · Cited by 464
Doody, R. S., Gavrilova, S. I., Sano, M., Thomas, R. G., Aisen, P. S., Bachurin, S. O., Seely, L., & Hung, D. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61074-0 · Cited by 460
β2-Adrenoreceptor is a regulator of the α-synuclein gene driving risk of Parkinson’s disease
Mittal, S., Bjørnevik, K., Im, D. S., Flierl, A., Dong, X., Locascio, J. J., Abo, K. M., Long, E., Jin, M., Xu, B., et al. (2017) · Science · doi:10.1126/science.aaf3934 · Cited by 416
Zhang, B., Maiti, A., Shively, S., Lakhani, F., McDonald-Jones, G., Bruce, J., Lee, E. B., Xie, S. X., Joyce, S., Li, C., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0406361102 · Cited by 413
Wang, I.-F., Guo, B.-S., Liu, Y.-C., Wu, C.-C., Yang, C.-H., Tsai, K.-J., & Shen, C.-K. J. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1206362109 · Cited by 377
Qing, H., He, G., Ly, P. T. T., Fox, C. J., Staufenbiel, M., Cai, F., Zhang, Z., Wei, S., Sun, X., Chen, C.-H., et al. (2008) · The Journal of Experimental Medicine · doi:10.1084/jem.20081588 · Cited by 364
Perry, T., Lahiri, D. K., Sambamurti, K., Chen, D., Mattson, M. P., Egan, J. M., & Greig, N. H. (2003) · Journal of Neuroscience Research · doi:10.1002/jnr.10611 · Cited by 347
A randomized, double-blind, placebo-controlled trial of simvastatin to treat Alzheimer disease
Sano, M., Bell, K. L., Galasko, D., Galvin, J. E., Thomas, R. G., van Dyck, C. H., & Aisen, P. S. (2011) · Neurology · doi:10.1212/wnl.0b013e318228bf11 · Cited by 336
Wang, J., Ho, L., Chen, L., Zhao, Z., Zhao, W., Qian, X., Humala, N., Seror, I., Bartholomew, S., Rosendorff, C., et al. (2007) · Journal of Clinical Investigation · doi:10.1172/jci31547 · Cited by 335
Sleire, L., Førde, H. E., Netland, I. A., Leiss, L., Skeie, B. S., & Enger, P. Ø. (2017) · Pharmacological Research · doi:10.1016/j.phrs.2017.07.013 · Cited by 329
Hebron, M. L., Lonskaya, I., & Moussa, C. E. H. (2013) · Human Molecular Genetics · doi:10.1093/hmg/ddt192 · Cited by 325
Modulation of memory by insulin and glucose: Neuropsychological observations in Alzheimer’s disease
Watson, G. S., & Craft, S. (2004) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2004.02.048 · Cited by 307
The hallmarks of Parkinson's disease
Antony, P. M. A., Diederich, N. J., Krüger, R., & Balling, R. (2013) · The FEBS Journal · doi:10.1111/febs.12335 · Cited by 300
Perry, T., Lahiri, D. K., Chen, D., Zhou, J., Shaw, K. T. Y., Egan, J. M., & Greig, N. H. (2002) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.300.3.958 · Cited by 300
Inhibition of Amyloid β Protein Aggregation and Neurotoxicity by Rifampicin
Tomiyama, T., Shoji, A., Kataoka, K.-I., Suwa, Y., Asano, S., Kaneko, H., & Endo, N. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.12.6839 · Cited by 295
Halliday, M., Radford, H., Zents, K. A. M., Molloy, C., Moreno, J. A., Verity, N. C., Smith, E., Ortori, C. A., Barrett, D. A., Bushell, M., et al. (2017) · Brain · doi:10.1093/brain/awx074 · Cited by 293
Nebes, R. D., Pollock, B. G., Houck, P. R., Butters, M. A., Mulsant, B. H., Zmuda, M. D., & Reynolds, C. F. (2003) · Journal of Psychiatric Research · doi:10.1016/s0022-3956(02)00085-7 · Cited by 275
Ding, Y., Qiao, A., Wang, Z., Goodwin, J. S., Lee, E.-S., Block, M. L., Allsbrook, M., McDonald, M. P., & Fan, G.-H. (2008) · The Journal of Neuroscience · doi:10.1523/jneurosci.3153-08.2008 · Cited by 269
Nilotinib Effects in Parkinson’s disease and Dementia with Lewy bodies
Pagan, F., Hebron, M., Valadez, E. H., Torres-Yaghi, Y., Huang, X., Mills, R. R., Wilmarth, B. M., Howard, H., Dunn, C., Carlson, A., et al. (2016) · Journal of Parkinson’s Disease · doi:10.3233/jpd-160867 · Cited by 265
Carro, E., & Torres-Aleman, I. (2004) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2004.02.050 · Cited by 262
A Randomized, Controlled Trial of Doxycycline and Rifampin for Patients with Alzheimer's Disease
Loeb, M. B., Molloy, D. W., Smieja, M., Standish, T., Goldsmith, C. H., Mahony, J., Smith, S., Borrie, M., Decoteau, E., Davidson, W., et al. (2004) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.2004.52109.x · Cited by 241
Cudkowicz, M. E., Titus, S., Kearney, M., Yu, H., Sherman, A., Schoenfeld, D., Hayden, D., Shui, A., Brooks, B., Conwit, R., et al. (2014) · The Lancet Neurology · doi:10.1016/s1474-4422(14)70222-4 · Cited by 241
Brain renin-angiotensin—A new look at an old system
Wright, J. W., & Harding, J. W. (2011) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2011.07.001 · Cited by 233
Up‐regulation of the α‐secretase ADAM10 by retinoic acid receptors and acitretin
Tippmann, F., Hundt, J., Schneider, A., Endres, K., & Fahrenholz, F. (2009) · The FASEB Journal · doi:10.1096/fj.08-121392 · Cited by 224
Chronic Divalproex Sodium to Attenuate Agitation and Clinical Progression of Alzheimer Disease
Tariot, P. N. (2011) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2011.72 · Cited by 223
A bibliometric review of drug repurposing
Baker, N. C., Ekins, S., Williams, A. J., & Tropsha, A. (2018) · Drug Discovery Today · doi:10.1016/j.drudis.2018.01.018 · Cited by 206
Cladribine: Mode of Action and Implications for Treatment of Multiple Sclerosis
Leist, T. P., & Weissert, R. (2011) · Clinical Neuropharmacology · doi:10.1097/wnf.0b013e318204cd90 · Cited by 201
Neurodegenerative disease: Brain windfall
Gammon, K. (2014) · Nature · doi:10.1038/nj7526-299a · Cited by 200
Gleevec inhibits β-amyloid production but not Notch cleavage
Netzer, W. J., Dou, F., Cai, D., Veach, D., Jean, S., Li, Y., Bornmann, W. G., Clarkson, B., Xu, H., & Greengard, P. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1534745100 · Cited by 194
Tadalafil crosses the blood–brain barrier and reverses cognitive dysfunction in a mouse model of AD
García-Barroso, C., Ricobaraza, A., Pascual-Lucas, M., Unceta, N., Rico, A. J., Goicolea, M. A., Sallés, J., Lanciego, J. L., Oyarzabal, J., Franco, R., et al. (2013) · Neuropharmacology · doi:10.1016/j.neuropharm.2012.06.052 · Cited by 184
Trías, E., Ibarburu, S., Barreto‐Núñez, R., Babdor, J., Maciel, T. T., Guillo, M., Gros, L., Dubreuil, P. C., Díaz‐Amarilla, P., Cassina, P., et al. (2016) · Journal of Neuroinflammation · doi:10.1186/s12974-016-0620-9 · Cited by 169
Protein kinase and protein phosphatase expression in amyotrophic lateral sclerosis spinal cord
Hu, J. ‐., Zhang, H., Wagey, R., Krieger, C., & Pelech, S. L. (2003) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2003.01670.x · Cited by 164
Brunden, K. R., Yao, Y., Potuzak, J. S., Ferrer, N. I., Ballatore, C., James, M. J., Hogan, A.-M. L., Trojanowski, J. Q., Smith, A. B., & Lee, V. M.-Y. (2011) · Pharmacological Research · doi:10.1016/j.phrs.2010.12.002 · Cited by 161
Protective Effects of Intranasal Losartan in the APP/PS1 Transgenic Mouse Model of Alzheimer Disease
Danielyan, L., Klein, R., Hanson, L. R., Buadze, M., Schwab, M., Gleiter, C. H., & Frey, W. H. (2010) · Rejuvenation Research · doi:10.1089/rej.2009.0944 · Cited by 158
Zhang, J., Guo, J., Zhao, X., Chen, Z., Wang, G., Liu, A., Wang, Q., Zhou, W., Xu, Y., & Wang, C. (2013) · Behavioural Brain Research · doi:10.1016/j.bbr.2013.05.017 · Cited by 156
Ibudilast in relapsing-remitting multiple sclerosis
Barkhof, F., Hulst, H. E., Drulovic, J. S., Uitdehaag, B. M. J., Matsuda, K., & Landin, R. (2010) · Neurology · doi:10.1212/wnl.0b013e3181d7d651 · Cited by 154
Current Pharmacological Approaches to Reduce Chorea in Huntington’s Disease
Coppen, E. M., & Roos, R. A. C. (2016) · Drugs · doi:10.1007/s40265-016-0670-4 · Cited by 153
Arun, T., Tomassini, V., Sbardella, E., de Ruiter, M. B., Matthews, L., Leite, M. I., Gelineau‐Morel, R., Cavey, A., Vergo, S. B., Craner, M., et al. (2013) · Brain · doi:10.1093/brain/aws325 · Cited by 145
Thalidomide: Emerging Role in Cancer Medicine
Richardson, P. G. G., Hideshima, T., & Anderson, K. C. (2002) · Annual Review of Medicine · doi:10.1146/annurev.med.53.082901.104043 · Cited by 141
Clinical efficacy of edaravone for the treatment of amyotrophic lateral sclerosis
Sawada, H. (2017) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2017.1319937 · Cited by 139
Grossi, C., Francese, S., Casini, A., Rosi, M. C., Luccarini, I., Fiorentini, A., Gabbiani, C., Luigi Messori, A., Moneti, G., & Casamenti, F. (2009) · Journal of Alzheimer s Disease · doi:10.3233/jad-2009-1063 · Cited by 132
Riluzole and amyotrophic lateral sclerosis survival: a population‐based study in southern Italy
Zoccolella, S., Beghi, E., Palagano, G., Fraddosio, A., Guerra, V., Samarelli, V., Lepore, V. L., Simone, I. L., Lamberti, P., Serlenga, L., et al. (2007) · European Journal of Neurology · doi:10.1111/j.1468-1331.2006.01575.x · Cited by 131
Molloy, D. W., Standish, T., Zhou, Q. X., Guyatt, G. H., & The DARAD Study Group (2012) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.3846 · Cited by 129
González-Lizárraga, F., Socías, S. B., Ávila, C. L., Torres-Bugeau, C. M., Barbosa, L. R. S., Binolfi, A., Sepúlveda-Díaz, J. E., Del-Bel, E., Fernandez, C. O., Papy-Garcia, D., et al. (2017) · Scientific Reports · doi:10.1038/srep41755 · Cited by 119
Mark, R. J., Ashford, J. W., Goodman, Y., & Mattson, M. P. (1995) · Neurobiology of Aging · doi:10.1016/0197-4580(94)00150-2 · Cited by 117
Diomede, L., Cassata, G., Fiordaliso, F., Salio, M., Ami, D., Natalello, A., Doglia, S. M., Luigi, A. D., & Salmona, M. (2010) · Neurobiology of Disease · doi:10.1016/j.nbd.2010.07.002 · Cited by 116
Čulman, J., Blume, A., Gohlke, P., & Unger, T. (2002) · Journal of Human Hypertension · doi:10.1038/sj.jhh.1001442 · Cited by 114
Борисович, Б. И. (2010) · Drug News & Perspectives · doi:10.1358/dnp.2010.23.8.1500435 · Cited by 100
The N-methyl-D-aspartate antagonist memantine retards progression of Huntington’s disease
Beister, A., Kraus, P., Kuhn, W., Dose, M., Weindl, A., & Gerlach, M. (2004) · Journal of neural transmission. Supplementum · doi:10.1007/978-3-7091-0579-5_14 · Cited by 98
Tamibarotene: A Candidate Retinoid Drug for Alzheimer’s Disease
Fukasawa, H., Nakagomi, M., Yamagata, N., Katsuki, H., Kawahara, K., Kitaoka, K., Miki, T., & Shudo, K. (2012) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.b12-00314 · Cited by 91
Towards Retinoid Therapy for Alzheimers Disease
Shudo, K., Fukasawa, H., Nakagomi, M., & Yamagata, N. (2009) · Current Alzheimer Research · doi:10.2174/156720509788486581 · Cited by 91
Drug Repurposing Is a New Opportunity for Developing Drugs against Neuropsychiatric Disorders
Lee, H.-M., & Kim, Y. (2016) · Schizophrenia Research and Treatment · doi:10.1155/2016/6378137 · Cited by 91
Xiong, H., Chen, Z., Wang, J., Song, J., Zhao, G., Shen, H., & Deng, Y. (2013) · Journal of Alzheimer s Disease · doi:10.3233/jad-130584 · Cited by 90
A Review: Treatment of Alzheimer’s Disease Discovered in Repurposed Agents
Appleby, B. S., Nacopoulos, D. A., Milano, N. J., Zhong, K., & Cummings, J. L. (2013) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000345791 · Cited by 90
Bomba, M., Ciavardelli, D., Silvestri, E., Canzoniero, L. M. T., Lattanzio, R., Chiappini, P. B. O., Piantelli, M., Ilio, C. D., Consoli, A., & Sensi, S. L. (2013) · Cell Death and Disease · doi:10.1038/cddis.2013.139 · Cited by 89
Olanzapine in Huntington's disease
Paleacu, D., Anca, M., & Giladi, N. (2002) · Acta Neurologica Scandinavica · doi:10.1034/j.1600-0404.2002.01197.x · Cited by 89
Heinrich, M. (2010) · The Alkaloids. Chemistry and biology/The alkaloids. Chemistry and biology · doi:10.1016/s1099-4831(10)06804-5 · Cited by 85
Ryu, J. K., & McLarnon, J. G. (2007) · Neurobiology of Disease · doi:10.1016/j.nbd.2007.08.019 · Cited by 85
Costa, A. R., Speretta, E., Crowther, D. C., & Cardoso, I. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.274548 · Cited by 81
Bharadwaj, P. R., Bates, K. A., Porter, T., Teimouri, E., Perry, G. L., Steele, J., Gandy, S., Groth, D., Martins, R. N., & Verdile, G. (2013) · Translational Psychiatry · doi:10.1038/tp.2013.97 · Cited by 81
Identification of Antihypertensive Drugs Which Inhibit Amyloid-β Protein Oligomerization
Zhao, W., Wang, J., Ho, L., Ono, K., Teplow, D. B., & Pasinetti, G. M. (2009) · Journal of Alzheimer s Disease · doi:10.3233/jad-2009-0925 · Cited by 78
Jarvis, C. I., Goncalves, M. B. C. V., Clarke, E. E., Dogruel, M., Kalindjian, S. B., Thomas, S. A., Maden, M., & Corcoran, J. P. T. (2010) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2010.07426.x · Cited by 78
Bulgarelli, I., Tamiazzo, L., Bresciani, E., Rapetti, D., Caporali, S., Lattuada, D., Locatelli, V., & Torsello, A. (2009) · Journal of Neuroscience Research · doi:10.1002/jnr.22088 · Cited by 78
Quetiapine in the Treatment of Behavioral Disturbances in Patients With Huntington’s Disease
Alpay, M., & Koroshetz, W. J. (2005) · Psychosomatics · doi:10.1176/appi.psy.47.1.70 · Cited by 78
Risperidone and the Treatment of Psychiatric, Motor, and Cognitive Symptoms in Huntington's Disease
Duff, K., Beglinger, L. J., O'Rourke, M. E., Nopoulos, P., Paulson, H. L., & Paulsen, J. S. (2008) · Annals of Clinical Psychiatry · doi:10.1080/10401230701844802 · Cited by 77
Riederer, P. F., & Müller, T. H. (2018) · Journal of Neural Transmission · doi:10.1007/s00702-018-1876-2 · Cited by 73
Tetrabenazine in the treatment of Huntington’s disease
Paleacu, D. (2007) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.a929 · Cited by 72
Sparks, D. L., Sabbagh, M., Connor, D. J., Lopez, J., Launer, L. J., Petanceska, S. S., Browne, P. J., Wassar, D., Johnson‐Traver, S., & Lochhead, J. J. (2005) · Current Alzheimer Research · doi:10.2174/1567205054367900 · Cited by 71
The Case of Galantamine: Repurposing and Late Blooming of a Cholinergic Drug
Mucke, H. A. (2015) · Future Science OA · doi:10.4155/fso.15.73 · Cited by 71
Meco, A. D., Lauretti, E., Vagnozzi, A. N., & Praticò, D. (2014) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2014.05.016 · Cited by 66
The emerging role of bexarotene in the treatment of Alzheimer’s disease: current evidence
Tousi, B. (2015) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s61309 · Cited by 65
Bachmeier, C. J., Beaulieu‐Abdelahad, D., MULLAN, M. J., & Paris, D. (2011) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2011.03.048 · Cited by 64
Chui, D., Tabira, T., Izumi, S., Koya, G., & Ogata, J. (1994) · PubMed Central · Cited by 63
Antiviral agents in Alzheimer’s disease: hope for the future?
Wozniak, M. A., & Itzhaki, R. F. (2010) · Therapeutic Advances in Neurological Disorders · doi:10.1177/1756285610370069 · Cited by 59
Valproic acid enhances microglial phagocytosis of amyloid-β1–42
Smith, A. M., Gibbons, H. M., & Dragunow, M. (2010) · Neuroscience · doi:10.1016/j.neuroscience.2010.04.041 · Cited by 54
Hayes, C. D., Dey, D., Palavicini, J. P., Wang, H., Patkar, K. A., Minond, D., Nefzi, A., & Lakshmana, M. K. (2013) · BMC Medicine · doi:10.1186/1741-7015-11-81 · Cited by 52
Lucchi, C., Curia, G., Vinet, J., Gualtieri, F., Bresciani, E., Locatelli, V., Torsello, A., & Biagini, G. (2013) · PLoS ONE · doi:10.1371/journal.pone.0072716 · Cited by 49
The Future of Drug Repositioning
Doan, T. L., Pollastri, M. P., Walters, M. A., & Georg, G. I. (2011) · Annual reports in medicinal chemistry · doi:10.1016/b978-0-12-386009-5.00004-7 · Cited by 48
Devos, D., Moreau, C., Delval, A., Dujardin, K., Defebvre, L., & Bordet, R. (2012) · CNS Drugs · doi:10.1007/s40263-012-0017-y · Cited by 47
Tiapride in the treatment of Huntington's chorea
Roos, R. A. C., Buruma, O. J. S., Bruyn, G. W., Kemp, B., & van der Velde, E. A. (1982) · Acta Neurologica Scandinavica · doi:10.1111/j.1600-0404.1982.tb03060.x · Cited by 46
Is Exenatide a Treatment for Parkinson’s Disease?
Athauda, D. S., Wyse, R. K. H., Brundin, P., & Foltynie, T. (2017) · Journal of Parkinson s Disease · doi:10.3233/jpd-171192 · Cited by 44
Cuenca, N. C., del Pozo, J. S. G., & Jordán, J. (2013) · Journal of Alzheimer s Disease · doi:10.3233/jad-130872 · Cited by 42
The promise and challenges of drug repurposing in psychiatry
Fava, M. (2018) · World Psychiatry · doi:10.1002/wps.20481 · Cited by 40
Hanyu, H., Hirao, K., Shimizu, S., Iwamoto, T., Koizumi, K., & Abe, K. (2007) · Nuclear Medicine Communications · doi:10.1097/mnm.0b013e32804c58aa · Cited by 39
No effect of anti-leprosy drugs in the prevention of Alzheimer’s disease and β-amyloid neurotoxicity
Endoh, M., Kunishita, T., & Tabira, T. (1999) · Journal of the Neurological Sciences · doi:10.1016/s0022-510x(99)00057-x · Cited by 38
Amphotericin B Binds to Amyloid Fibrils and Delays Their Formation: A Therapeutic Mechanism?
Hartsel, S. C., & Weiland, T. R. (2003) · Biochemistry · doi:10.1021/bi0270384 · Cited by 38
Drugs in clinical development for the treatment of amyotrophic lateral sclerosis
Martínez, A., Palomo, V., Pérez, D. I., & Gil, C. (2017) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2017.1302426 · Cited by 36
Hassanzadeh, G., Hosseini, A., Pasbakhsh, P., Akbari, M., Ghaffarpour, M., Takzare, N., & Zahmatkesh, M. (2015) · PubMed · Cited by 34
Do Cancer Drugs Counteract Neurodegeneration? Repurposing for Alzheimer’s Disease
Monacelli, F., Cea, M., Borghi, R., Odetti, P. R., & Nencioni, A. (2016) · Journal of Alzheimer s Disease · doi:10.3233/jad-160840 · Cited by 31
The importance of drug metabolites synthesis: the case-study of cardiotoxic anticancer drugs
Hrynchak, I., Sousa, E., Pinto, M. M. M., & Costa, V. M. (2017) · Drug Metabolism Reviews · doi:10.1080/03602532.2017.1316285 · Cited by 31
Self-citationNeuropathological Analysis of Dementia in a Japanese Leprosarium
Goto, M., Kimura, T., HAGIO, S., Ueda, K., Kitajima, S., Tokunaga, H., & Sato, E. (1995) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000106939 · Cited by 30
Neuronal plasticity and ageing processes in the frame of the ‘Red Queen Theory’
Agnati, L. F., Zoli, M., Biagini, G., & Fuxé, K. (1992) · Acta Physiologica Scandinavica · doi:10.1111/j.1748-1716.1992.tb09370.x · Cited by 26
Existence of senile plaques in the brains of elderly leprosy patients
Kimura, T., & Goto, M. (1993) · The Lancet · doi:10.1016/0140-6736(93)92274-w · Cited by 23
Brain Aging and Neuronal Plasticitya
AGNATIC, L. F., Benfenati, F., Solfrini, V., Biagini, G., Fuxé, K., Guidolin, D., Carani, C., & Zini, I. (1992) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1992.tb27451.x · Cited by 20
An update on cladribine for relapsing-remitting multiple sclerosis
Holmøy, T., Torkildsen, Ø., & Myhr, K. (2017) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2017.1372747 · Cited by 20
Amphotericin B interactions with soluble oligomers of amyloid Abeta1-42 peptide.
Smith, N. W., Annunziata, O., & Dzyuba, S. (2009) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2009.02.016 · Cited by 19
Trimetazidine in conditions other than coronary disease, old drug, new tricks?
Zou, H., Zhu, X., Ding, Y., Jin, Q., Qian, L.-Y., Huang, D., & Cen, X.-J. (2017) · International Journal of Cardiology · doi:10.1016/j.ijcard.2017.02.083 · Cited by 18
Exenatide – a drug for diabetes and Parkinson disease?
Jankovic, J. J. (2017) · Nature Reviews Neurology · doi:10.1038/nrneurol.2017.140 · Cited by 17
Acylated and unacylated ghrelin confer neuroprotection to mesencephalic neurons
Wagner, J., Vulinović, F., Grünewald, A., Unger, M. M., Möller, J. C., Klein, C., Michel, P. P., Ries, V., Oertel, W. H., & Alvarez‐Fischer, D. (2017) · Neuroscience · doi:10.1016/j.neuroscience.2017.09.045 · Cited by 15
Chemotherapy with cytotoxic and cytostatic agents in brain cancer
Blakeley, J. O., & Grossman, S. A. (2012) · Handbook of clinical neurology · doi:10.1016/b978-0-444-52138-5.00017-7 · Cited by 12
Cited by
The Expanding Role of Pyridine and Dihydropyridine Scaffolds in Drug Design
Ling, Y., Hao, Z.-Y., Liang, D., Zhang, C.-L., Liu, Y.-F., & Wang, Y. (2021) · Drug Design, Development and Therapy · doi:10.2147/dddt.s329547 · Cited by 414
Gadhave, D. G., Sugandhi, V. V., Jha, S. K., Nangare, S. N., Gupta, G., Singh, S. K., Dua, K., Cho, H., Hansbro, P. M., & Paudel, K. R. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102357 · Cited by 358
Li, J., & Kataoka, K. (2021) · Journal of the American Chemical Society · doi:10.1021/jacs.0c09029 · Cited by 281
Progress and Challenges in Targeted Protein Degradation for Neurodegenerative Disease Therapy
Fang, Y., Wang, J., Zhao, M., Zheng, Q., Ren, C., Wang, Y., & Zhang, J. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c00844 · Cited by 100
Enhancing autophagy in Alzheimer's disease through drug repositioning
Eshraghi, M., Ahmadi, M., Afshar, S., Lorzadeh, S., Adlimoghaddam, A., Rezvani Jalal, N., West, R., Dastghaib, S., Igder, S., Torshizi, S. R. N., et al. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108171 · Cited by 89
Metadata
- Authors
- Durães, F., Pinto, M., & Sousa, E.
- Venue
- Pharmaceuticals
- Publisher
- MDPI AG
- Published
- 2018-05-11
- Volume
- 11
- Issue
- 2
- Pages
- 44
- ISSN
- 1424-8247 (ISSN-L)
- OpenAlex
- W2799817815
- Cited by
- 343
- References
- 117
- FWCI
- 17.67
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.